Bio

Ben founded RB Muskin LLC as a technology transfer / business development consulting firm in 2006 to provide a full range consulting services to colleges, universities, healthcare organizations, non-profit research institutions, as well as for-profit firms in the life sciences space. Working in close partnership with his clients, Ben is able to effectively and efficiently navigate the multitude of issues required for successful outcomes in these areas. Prior to RB Muskin, LLC, Ben was Co-Founder and Vice President of Business Development and Strategic Planning of CGI Pharmaceuticals (sold to Gilead Pharmaceuticals). Ben played a principal role in attracting and closing three rounds of venture financing for CGI totaling $62M. He also successfully negotiated and closed multiple collaborations and licenses with international pharmaceutical and biotechnology companies as well as with many non-profit organizations. Ben oversaw business and strategic planning activities in addition to managing diverse and complex patent estates. Prior to CGI, Ben served as Associate Director in Yale University’s Technology Transfer “Office of Cooperative Research”. During his four-year tenure at Yale, he successfully consummated dozens of license and sponsored research agreements. He also had lead responsibility for launching multiple Yale spinout companies (one of those companies was CGI Pharmaceuticals – see above). The successes Ben and his Yale colleagues achieved in the mid- late 1990s helped launch a culture of progressive technology transfer and entrepreneurship that continues to grow and thrive to this day. Earlier in Ben’s career, he was the Co-Founder and President of Spectrum Medical Technologies (licensed to DeRoyal Industries) and a project engineer / forensic engineer / and hospital consultant for ECRI Institute. Ben holds a BS in Physics/Engineering from Washington and Lee University and he pursued Master/PhD work in Biomedical Engineering at Drexel University.